Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$159.9MMiss by $39.8M
EPS-$1.81Miss by $0.58
Revenue estimate$199.8M
EPS estimate-$1.23

Next report

Aug 4, 2026 (In 5 days)
Revenue estimate$183.1M
EPS estimate-$1.21

Financials

Q3 2025

Income statement

See full
Revenue$159.9M+14.7%
Operating income-$170.9M-29.5%
Net income-$180.4M-35.1%
EPS (diluted)-$1.81-29.3%

Balance sheet

See full
Cash & equivalents$202.5M+34.5%
Total debt$33.8M—
Total equity$9.2M-97.4%
Total assets$1.2B-22.6%

Cash flow

See full
Operating cash flow-$91.4M-36.5%
CapEx$1.3M-21.0%
Free cash flow-$92.7M-35.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.9B-39.7%
Enterprise value$2.73B—
P/S4.6×-4.6×

Profitability

See full
Operating margin-86.4%-11.8pp
Net margin-92%-11.4pp
FCF margin-71.5%-7.9pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio1.9×-0.9×

Segments

By geography

See full
North America$83.5M+8.6%
Latin America$43.4M+14.0%
EMEA$27.9M+25.5%
Asia Pacific$5.2M+123%

By product

See full
Collaboration And Royalty$111.9M+14.4%
Royalty$64.9M+4.3%
Non Cash Royalty$24.9M+8.1%

Versus estimates

Revenue

Q1 2026$136.0MMiss by $22.2MQ4 2025$207.0MBeat by $8.4M
Q3 2025$159.9MMiss by $39.8M
Q2 2025$166.5MBeat by $547.9KQ1 2025$139.3MMiss by $23.1MQ4 2024$164.9MBeat by $6.2M

Diluted EPS

Q1 2026-$1.84Miss by $0.35Q4 2025-$1.29Miss by $0.09
Q3 2025-$1.81Miss by $0.58
Q2 2025-$1.17Beat by $0.10Q1 2025-$1.57Miss by $0.03Q4 2024-$1.39Miss by $0.07

Ask the moment Ultragenyx Pharmaceutical reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Ultragenyx Pharmaceutical report Q3 2025 earnings?
Ultragenyx Pharmaceutical (RARE) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Ultragenyx Pharmaceutical's Q3 2025 revenue and EPS?
Ultragenyx Pharmaceutical reported revenue of $159.9M and eps of $-1.81 for Q3 2025.
Did Ultragenyx Pharmaceutical beat estimates in Q3 2025?
Revenue missed the consensus estimate of $199.8M by $39.8M. EPS missed the consensus estimate of $-1.23 by $0.58.
How did Ultragenyx Pharmaceutical's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 14.7% from $139.5M a year earlier and eps declined 29.3% from $-1.40.
Where can I find Ultragenyx Pharmaceutical's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-264707) and the 10-Q periodic report (0001193125-25-265126) directly on SEC EDGAR. The filing index links above go to sec.gov.